Adbry® (tralokinumab-ldrm) Autoinjector Now Available for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD) in the U.S.
LEO Pharma Inc. announced today the availability of the Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in ...
Monthly Prescribing Reference4d
Adbry Autoinjector Now Available for Adults With Atopic Dermatitis
A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic dermatitis not adequately controlled with topical ...
Morningstar6d
Adbry® (tralokinumab-ldrm) Autoinjector Now Available for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD) in the U.S.
Adbry is currently indicated in the U.S. for patients 12 years and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription ...
dermatologyadvisor6d
Adbry Autoinjector Now Available for Adults With Atopic Dermatitis
The Adbry autoinjector is for use in adults only. The Adbry autoinjector is available in a 300 mg/2 mL dosage strength and is intended for use in adults only. The device includes a push-down mechanism ...
PipelineReview.com5d
Adbry® (tralokinumab-ldrm) Autoinjector Now Available for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD) in the U.S.
Adbry is currently indicated in the U.S. for patients 12 years and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies ...
FDA approves Ebglyss for moderate-to-severe atopic dermatitis
The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...